Neurocrine acquires Soleno Therapeutics in $2.9 billion M&A deal, boosting private markets liquidity

Neurocrine Biosciences has announced its plan to acquire Soleno Therapeutics Inc for approximately $2.9 billion in cash, according to a press release on PR Newswire, marking a significant development in private credit market news and private markets liquidity news. The acquisition news was initially reported by the Financial Times, which said Neurocrine was nearing a deal to buy Soleno Therapeutics valued at more than $2.5 billion before the official agreement was announced.

The deal values Soleno at $53 per share, a 34% premium to its most recent closing price, and is expected to close within three months pending standard regulatory approvals. The transaction underscores the growing role of M&A deals in creating liquidity events and strengthening investor confidence in high-value private market investments.

This acquisition highlights the ongoing activity in venture capital funds and growth equity, as early investors in Soleno now have the opportunity to realize returns. The transaction reflects the broader trend of private markets liquidity news, where high-profile exits and acquisitions continue to shape capital allocation and investor sentiment.

Neurocrine M&A deal terms and liquidity event

Under the agreement, Neurocrine Biosciences will initiate a cash tender offer to purchase all outstanding shares of Soleno Therapeutics Inc, followed by a merger to make Soleno a wholly owned subsidiary. The purchase will be funded primarily through cash on hand and modest debt financing, ensuring a smooth transition for operations.

For existing investors, this represents a major liquidity event. Venture capital funds and growth equity investors that previously funded Soleno now have the ability to monetize their positions. Such events are critical in private markets liquidity news, demonstrating that private investments can deliver returns and encouraging further capital deployment in similar high-growth sectors.

Soleno acquisition expands Neurocrine growth equity portfolio

The acquisition gives Neurocrine access to VYKAT XR, the first FDA-approved therapy for hyperphagia associated with Prader-Willi syndrome, a rare metabolic disorder. The drug has already shown strong early adoption, generating an estimated $190 million in revenue in 2025, and is expected to be a key growth driver for Neurocrine.

By acquiring Soleno, Neurocrine Biosciences expands its rare disease portfolio alongside products such as Ingrezza and Crenessity, enhancing both real capital markets pricing and investor confidence. The transaction also strengthens the company’s competitive position in metabolic disease treatment and demonstrates a disciplined approach to growth via M&A deals.

Private markets liquidity news: how venture capital and growth equity investors benefit

For the private market ecosystem, the acquisition is notable in several ways:

Liquidity event – Existing shareholders, including venture capital funds and growth equity participants, receive cash for their holdings, realizing returns on their early investments.

Investor confidence – High-profile acquisitions in biotech bolster confidence in private markets, encouraging further investment in innovative companies.

Private markets activity – Deals like this demonstrate that capital continues to flow in private markets, supporting ongoing funding for startups and growth-stage businesses.

By creating a liquidity event, this transaction contributes directly to private markets liquidity news, showing that strategic exits and acquisitions are viable paths for investors to monetize early-stage bets.

Private credit market news and biotech M&A trends

The acquisition occurs during a period of heightened private credit market news, with significant activity in biotech and pharmaceutical sectors. Companies continue to pursue strategic acquisitions to expand their portfolios and capture near-term revenue, particularly in therapeutic areas with high unmet need.

Analysts note that the premium paid for Soleno reflects not only the near-term revenue potential from VYKAT XR but also long-term growth opportunities. With patent protection extending into the 2040s, the deal reinforces real capital markets pricing and ensures predictable cash flows for Neurocrine Biosciences, further strengthening investor confidence.

Additionally, this M&A deal signals that private market participants remain willing to back high-value companies, particularly those with proven commercial products. By demonstrating that early-stage investments can result in successful exits, the acquisition helps maintain the health and flow of capital in venture capital funds and growth equity ecosystems.

Real capital markets pricing and investor confidence boosted by acquisition

The $2.9 billion transaction highlights several key financial dynamics in private markets liquidity news:

Premium valuation – Soleno’s shares jumped over 30% upon news of the acquisition, illustrating how real capital markets pricing responds to strategic acquisitions.

Revenue certainty – VYKAT XR provides immediate, predictable revenue for Neurocrine, enhancing valuation metrics and supporting a sustainable growth model.

Investor returns – Early investors can realize substantial returns, creating positive reinforcement for continued investment in private markets.

The financial structure of the deal ensures both parties benefit: Soleno shareholders gain cash liquidity, and Neurocrine expands its product pipeline and market reach.

Neurocrine integration and private market growth outlook

Neurocrine Biosciences expects the acquisition to close in approximately 90 days, pending regulatory approvals and shareholder acceptance. Integration plans focus on scaling VYKAT XR distribution efficiently while maintaining high standards of patient care.

Looking forward, the acquisition is likely to encourage additional M&A deals in biotech and healthcare. The success of such high-profile transactions demonstrates that private and public market investors alike have confidence in the value creation potential of strategic acquisitions.

For private market participants, particularly those managing venture capital funds and growth equity, the Neurocrine–Soleno deal serves as a model of how liquidity events can generate returns while fostering broader sector growth. The transaction also reinforces private markets liquidity news, highlighting that capital continues to flow toward innovative companies with strong commercial potential.

Neurocrine–Soleno deal strengthens private markets and investor confidence

The acquisition of Soleno Therapeutics Inc by Neurocrine Biosciences highlights the ongoing vitality of the private credit market and underscores the importance of liquidity events in maintaining investor confidence. This M&A deal demonstrates how strategic acquisitions create value for early investors, support real capital markets pricing, and sustain activity in venture capital funds and growth equity.

As high-profile transactions like this continue, 2026 is shaping up to be a pivotal year for private markets liquidity news, signaling renewed activity, confidence, and strategic capital deployment in innovative sectors such as biotech and rare diseases.

About UCapital.com

UCapital is a global financial intelligence and news platform. It combines timely market coverage and in-depth analysis with access to curated deal opportunities, connecting investors and financial professionals to private market activity.